WeVote
Log In

Bill

Bill

SB 82

Legislative ethics training; requiring certain amount of training for legislators; requiring reporting and enforcement. Effective date.

2025 Regular Session Introduced by Julia Kirt

An interstate compact creates a Commission to review proposed cures, award prizes, and require IP transfer; funds prizes via royalties to speed cures and cut public health costs.

Second Reading referred to Rules
0
WeVote Research Nonpartisan
Bill Summary · SB 82

SB 82 — Compact to Award Prizes for Curing Disease

Status: Introduced Jan 17, 2025; Passed 1st Reading
Subject areas: Compacts; Public health; Disease; Interstate cooperation; Awards & commissions

Main purpose

SB 82 would enact an interstate compact establishing a multistate body — the “Solemn Covenant of the States Commission” — to (1) evaluate proposed treatments and therapeutic protocols that claim to cure diseases, (2) award large monetary prizes to validated cure winners, and (3) make approved cures widely available while financing prize payments through a dedicated royalty/fee regime and other Commission resources.

The compact’s policy goal is to create a new incentive mechanism (prizes plus IP transfer/availability conditions) to accelerate development, distribution, and public adoption of cures that materially reduce public health costs.

Key provisions

  • Compact trigger: the Commission is created once at least six states enact the compact.
  • Commission membership and governance:
    • One member per compacting state (each state decides appointment rules).
    • The Commission is a corporate, interstate instrumentality with bylaws/rules that have the force of law in compacting states.
    • Quorum, voting, committees, budget, and personnel authorities are delegated to the Commission.
  • Review and prize process:
    • The Commission will receive and rapidly review submitted treatments/protocols and may award a prize to submissions that meet its standards for a “successful cure.”
    • Prize award conditions include a requirement that the prize winner transfer any intellectual property necessary for manufacturing/distribution (per Commission rules).
  • Availability and pricing of cures:
    • For compacting states, the Commission will set a selling price for the cure limited to manufacturing/distribution/regulatory cost (no extra markup).
    • For non‑compacting states or foreign markets, the Commission may collect royalty fees from manufacturers/providers. Cumulative royalties are capped at an amount equal to the estimated five‑year public‑health savings for the jurisdiction (as calculated by Commission‑retained actuaries).
  • Use of royalty proceeds:
    • Pay/reimburse prize payments and Commission costs (including actuarial calculations and interest on loans used for prizes).
    • Any surplus is annually refunded to compacting states pro rata based on each state’s prize obligation share.
  • Commission powers include subpoena authority, contracting, hiring staff, borrowing money, accepting donations, owning property, and enforcing compliance with bylaws.
  • Dispute resolution, monitoring, and enforcement mechanisms among compacting states are provided. (Commission rules to govern details.)
  • Withdrawal and suspension: the compact provides processes for a state to withdraw or be suspended (text establishes governance but specifics follow Commission bylaws and compact terms).

Who is affected

  • State governments that join (compacting states): potential obligations to fund or share in prize payments, participation in governance, and access to lower-priced cures.
  • Taxpayers / public health budgets: potential long‑term savings from cures; short‑term fiscal exposures if states participate in prize obligations or bridge financing is required.
  • Medical innovators, pharmaceutical and biotech manufacturers: new prize‑based alternative to patent/licensing incentives; conditioned IP transfer and pricing terms could affect commercial strategy.
  • Patients and health systems: faster access to validated cures, potentially at prices limited for participating states.
  • Non‑compacting states & foreign buyers: manufacturers may pay royalties; cure pricing and access may differ by jurisdiction.

Procedural/timing aspects

  • The Commission becomes operative only after six states enact the compact.
  • The Commission will adopt bylaws and rules (binding in member states) that spell out standards for “cure” adjudication, prize calculation and claiming, IP transfer mechanics, actuarial methods, and enforcement procedures.
  • Prize funding model contemplates using royalty collections, membership dues, donations, and borrowing; the Commission may borrow to make prize payments and then reimburse via later royalties/refunds.

Potential impacts and considerations

  • Pros: creates a focused, multistate mechanism to reward verified cures; could accelerate translation of breakthrough treatments into broad public benefit and reduce long‑term public health spending.
  • Tradeoffs and risks: legal/contractual issues around IP transfer, potential pushback from innovators over conditioned pricing, administrative and startup costs, and complexity in estimating public‑health savings and calibrating royalties. Fiscal exposure for member states depends on prize size, financing approach, and actual cure impact.

This summary presents SB 82’s structure and anticipated effects as drafted in the compact text. The implementing bylaws and prize rules — which will determine many operational details and fiscal outcomes — are to be adopted by the Commission after the compact achieves the required state enactments.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.